Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 1.00 |
| ▸ | GALR3 | O60755 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | NR2F2 | P24468 | 1/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 1/20 | 1.00 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 6/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Carboxyamidotriazole SCHEMBL8467240 | 0.99 | SMN1; SMN2 (0.98) | SMN1; SMN2GALR3CYP3A4CYP2C9NR2F2 | |
| SCHEMBL17507850 | 0.93 | SMN1; SMN2 (0.88) | SMN1; SMN2GALR3CYP3A4CYP2C9NR2F2 | |
| SCHEMBL7264241 | 0.92 | SMN1; SMN2 (0.86) | SMN1; SMN2GALR3CYP3A4CYP2C9NR2F2 | |
| SCHEMBL12795019 | 0.91 | SMN1; SMN2 (0.83) | SMN1; SMN2GALR3CYP3A4CYP2C9NR2F2 | |
| SCHEMBL7280524 | 0.91 | SMN1; SMN2 (0.83) | SMN1; SMN2GALR3CYP3A4CYP2C9NR2F2 | |
| SCHEMBL28938726 | 0.90 | SMN1; SMN2 (0.81) | SMN1; SMN2GALR3CYP3A4CYP2C9NR2F2 | |
| SCHEMBL7271739 | 0.90 | SMN1; SMN2 (0.81) | SMN1; SMN2GALR3CYP3A4CYP2C9NR2F2 | |
| SCHEMBL7265907 | 0.89 | SMN1; SMN2 (0.80) | SMN1; SMN2GALR3CYP3A4CYP2C9NR2F2 | |
| SCHEMBL7264526 | 0.89 | SMN1; SMN2 (0.80) | SMN1; SMN2GALR3CYP3A4CYP2C9NR2F2 | |
| SCHEMBL7264556 | 0.88 | SMN1; SMN2 (0.78) | SMN1; SMN2GALR3CYP3A4CYP2C9NR2F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 13453 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4735045-A2 | OXAZAPHOSPHORINE ANTIBODY DRUG CONJUGATES AND METHODS OF USE | La Life Products, LLC (US) | 2026-05-06 | — | — | EP | claimed |
| US-12594262-B2 | CAI nanoemulsions | FORWARDVUE PHARMA, INC. (US) | 2026-04-07 | — | — | US | claimed |
| EP-4717275-A1 | ANTI-LUNG CANCER COMBINED DRUG AND USE THEREOF | Gunagdong Yinzhu Pharmaceutical Technology Co., Ltd (CN) | 2026-04-01 | — | — | EP | claimed |
| US-20260076969-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2026-03-19 | — | — | US | claimed |
| EP-4192452-B1 | COMPOSITIONS COMPRISING CARBOXYAMIDOTRIAZOLE OROTATE FOR USE IN PREVENTING OR TREATING SARS-COV-2 INFECTION | TACTICAL THERAPEUTICS INC (US) | 2025-10-08 | — | — | EP | claimed |
| US-12364682-B2 | Use of tegaserod in preparation of anti-tumor drug | QINGDAO HAIJI BIOMEDICINE CO., LTD. (CN) | 2025-07-22 | — | — | US | claimed |
| US-20250170082-A1 | HPDL INHIBITORS AND USES THEREOF | NEW YORK UNIVERSITY (US) | 2025-05-29 | — | — | US | claimed |
| CN-119977778-A | Preparation method of carboxyamidotriazole intermediate | 广东银珠医药科技有限公司 | 2025-05-13 | — | — | CN | claimed |
| CN-119971050-A | Composition of carboxyamidotriazole and chemotherapeutic drug and application of composition in combination treatment of solid tumors | 广东银珠医药科技有限公司 | 2025-05-13 | — | — | CN | claimed |
| WO-2025085311-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF KMT2D-DEFICIENT CANCERS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-04-24 | — | — | WO | claimed |
| US-5861406-A | ANTICARCINOGENIC AGENTS AND ANTITUMOR AGENTS | CONSTANTIA GRUPPE (AT) | 1999-01-19 | — | — | US | claimed |
| EP-0840608-A1 | TREATMENT AND PREVENTION OF NEOPLASMS WITH SALTS OF AMINOIMIDAZOLE CARBOXAMIDE AND 5-AMINO OR SUBSTITUTED AMINO 1,2,3-TRIAZOLES | Constantia Gruppe (AT) | 1998-05-13 | — | — | EP | claimed |
| EP-0797438-A1 | INHIBITION OF RETROVIRAL LTR PROMOTERS BY CALCIUM RESPONSE MODIFIERS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1997-10-01 | — | — | EP | claimed |
| WO-1997003668-A1 | TREATMENT AND PREVENTION OF NEOPLASMS WITH SALTS OF AMINOIMIDAZOLE CARBOXAMIDE AND 5-AMINO OR SUBSTITUTED AMINO 1,2,3-TRIAZOLES | CONSTANTIA GRUPPE (AT) | 1997-02-06 | — | — | WO | claimed |
| US-5565478-A | Combination therapy using signal transduction inhibitors with paclitaxel and other taxane analogs | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH & HUMAN SERVICES (US) | 1996-10-15 | — | — | US | claimed |
| WO-1996018394-A1 | INHIBITION OF RETROVIRAL LTR PROMOTERS BY CALCIUM RESPONSE MODIFIERS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY OF THE DEPARTMENT OFHEALTH AND HUMAN SERVICES (US) | 1996-06-20 | — | — | WO | claimed |
| EP-0304221-B1 | 5-amino or substituted amino 1,2,3-triazoles useful as antiproliferative agents | MERCK & CO INC (US) | 1994-02-16 | — | — | EP | claimed |
| US-5045543-A | Treatment of cancer with high probability of metastasis | MERCK & CO., INC. (US) | 1991-09-03 | — | — | US | claimed |
| EP-0304221-A2 | 5-amino or substituted amino 1,2,3-triazoles useful as antiproliferative agents | MERCK & CO. INC. (US) | 1989-02-22 | — | — | EP | claimed |
| US-4590201-A | ANTICOCCIDIAL AGENT FOR ANIMALS PARTICULARLY FOR POULTRY | MERCK & CO., INC. (US) | 1986-05-20 | — | — | US | claimed |